Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Gut bacteria-produced exopolysaccharides (EPS) help regulate metabolism by modulating gut microbiota, promoting SCFA ...

GLP-1 (glucagon-like peptide-1) discovered in the 1980s functions as a hormone derived from the proglucagon sequence and was found to have a transformative impact on the treatment of diabetes and ...

Losing weight on a GLP-1 medication can have emotional and physical effects. Some changes are easier to handle than others, ...

But given the evidence in total, Al-Aly says, “I’m more encouraged about the future of GLP-1 and its potential promise.” The ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a significant contribution to the future obesity treatment industry.

The suit, which was filed on Wednesday, alleges the label "approved, published, and launched a campaign to create a viral hit out of a rap track" with Lamar's diss track Not Like Us, and that ...

The suit stems from the diss track “Not Like Us” by Kendrick Lamar, another UMG artist. Drake’s legal complaint also again accuses UMG of using bots on Spotify and other streaming platforms ...

and Spotify of artificially inflating the popularity of Kendrick Lamar’s diss track “Not Like Us,” less than two months after he first filed it. The action, filed in November, accused UMG ...